Company Overview#
SHMD develops AI-based brain health solutions for stroke prevention and early detection. The company pairs a wearable cerebral blood-flow device with a self-screening app, so users can check brain health risks without a hospital visit. It also runs an AI Medtech Lab in Seoul.
Technology & Product#
SHMD focuses on non-invasive brain health hardware and software:
- CEREBAND: A wearable AI device for stroke prevention, built on transcranial Doppler (TCD) sensing to measure and monitor cerebral blood flow.
- BRAINCHECK.AI: A self-screening app that combines four assessments in one place — stroke risk, cognitive function, carotid sound analysis, and headache evaluation. The carotid screening uses a patented AI algorithm, and the app was co-developed with the Korean Stroke Society.
Market & Use Cases#
The main users are people who want to track stroke and brain health risk at home, without clinical equipment. Because the screening runs on a smartphone in a few minutes, it fits preventive health programs, employer wellness checks, and follow-up monitoring for people with high blood pressure or other risk factors. CEREBAND extends this into continuous wearable monitoring of cerebral blood flow.
Traction & References#
- BRAINCHECK.AI has been used by more than 5,000 people across 34 countries, with clinical research behind its screening models(BRAINCHECK.AI).
- The company joined the NVIDIA Inception Program in 2025(VentureSquare).
- SHMD was selected across all TIPS tracks — startup commercialization, R&D, and overseas marketing — receiving about KRW 800 million in support(SHMD).
- It was selected for the Chungbuk IP Center’s IP-Nara program(Newsis) and designated a 2025 export-potential enterprise(Money Today).
Collaboration Relevance#
- Hospitals, health-screening centers, and insurers can run PoCs using BRAINCHECK.AI as an early stroke-risk screening layer before clinical referral.
- Wearable and medical-device partners can work with SHMD on TCD-based CEREBAND integration and validation.
- The 34-country app footprint gives a base for Korea-Europe market entry through distribution or clinical-study partners.